Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership
Partnership enables Moderna to leverage Caris' library of de-identified, multi-modal data and analytics.
Caris has announced a new agreement with Moderna in support of Moderna's oncology and novel therapeutics initiatives.
Through this multi-year agreement, Moderna will leverage Caris' library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses along with claims data to enhance development strategies for Moderna's oncology pipeline, including facilitation of clinical trial design.
"Partnering with Caris Life Sciences will support Moderna's oncology portfolio with clinico-genomics data from Caris' industry-leading and comprehensive suite of integrated precision medicine capabilities," stated Praveen Aanur, MD, MPH, MBA, vice president, oncology therapeutic area head of Moderna in a press release.
"We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives," said David Spetzler, MS, PhD, MBA, president of Caris Life Sciences. "The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna's innovative medicines."
Reference
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics. (24 October 2023). Cision PR Newswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
